Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Biotherapeutics Clinical Site 31
Markham, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 30
Windsor, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 19
Fremont, California, United States
- Arcutis Biotherapeutics Clinical Site 21
Santa Monica, California, United States
- Arcutis Biotherapeutics Clinical Site 42
Coral Gables, Florida, United States
- Arcutis Biotherapeutics Clinical Site 24
Miami, Florida, United States
- Arcutis Biotherapeutics Clinical Site 12
Tampa, Florida, United States
- Arcutis Biotherapeutics Clinical Site 10
Rolling Meadows, Illinois, United States
- Arcutis Biotherapeutics Clinical Site 22
Plainfield, Indiana, United States
- Arcutis Biotherapeutics Clinical Site 15
Louisville, Kentucky, United States
- Arcutis Biotherapeutics Clinical Site 28
Rockville, Maryland, United States
- Arcutis Biotherapeutics Clinical Site 40
Clinton Township, Michigan, United States
- Arcutis Biotherapeutics Clinical Site 20
Detroit, Michigan, United States
- Arcutis Biotherapeutics Clinical Site 14
Fridley, Minnesota, United States
- Arcutis Biotherapeutics Clinical Site 23
High Point, North Carolina, United States
- Arcutis Biotherapeutics Clinical Site 18
Bexley, Ohio, United States
- Arcutis Biotherapeutics Clinical Site 29
Portland, Oregon, United States
- Arcutis Biotherapeutics Clinical Site 27
Pittsburgh, Pennsylvania, United States
- Arcutis Biotherapeutics Clinical Site 13
Arlington, Texas, United States
- Arcutis Biotherapeutics Clinical Site 11
Austin, Texas, United States
- Arcutis Biotherapeutics Clinical Site 41
College Station, Texas, United States
- Arcutis Biotherapeutics Clinical Site 25
Houston, Texas, United States
- Arcutis Biotherapeutics Clinical Site 26
Pflugerville, Texas, United States
- Arcutis Biotherapeutics Clinical Site 17
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Dec 2019
- Primary completion
- 18 Aug 2020
- Completion
- 21 Aug 2020
- Last update posted
- 3 Jul 2023
- Registered enrollment
- 226
- Registry id
- NCT04091646
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.